Loading...

Reneo Pharmaceuticals, Inc.

RPHMNASDAQ
Healthcare
Biotechnology
$18.20
$16.47(952.02%)

Reneo Pharmaceuticals, Inc. (RPHM) Stock Overview

Explore Reneo Pharmaceuticals, Inc.’s financial performance, market position, analyst ratings, and future outlook.

Meyka AI Score

B

Score: 63.1/100

Key Financials

Market Cap60.8M
P/E Ratio22.18
EPS (TTM)$-16.80
ROE0.33%

AI Price Forecasts

1 WeekN/A
1 MonthN/A
3 MonthsN/A
1 Year Target$20.53

RPHM Stock Analysis & Investment Overview

Our comprehensive AI-powered analysis of Reneo Pharmaceuticals, Inc. (RPHM) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.

Our forecasting models predict significant price movements, with a 12-month target of $20.53.

Key financial metrics showcase the company's fundamental strength, including a P/E ratio of 22.18 and a market capitalization of 60.8M. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.

Stats data is not available for RPHMStats details for RPHM are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.
Analyst Recommendations data is not available for RPHMAnalyst Recommendations details for RPHM are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Company Profile

Reneo Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the development of therapies for patients with rare genetic mitochondrial diseases. It develops REN001, a selective peroxisome proliferator-activated receptor delta agonist, which is in Phase IIb clinical trial in patients with primary mitochondrial myopathies, as well as in Phase 1b clinical trial in patients with long-chain fatty acid oxidation disorders and glycogen storage disease type V. Reneo Pharmaceuticals, Inc. was incorporated in 2014 and is headquartered in San Diego, California.

CEO

Gregory J. Flesher

Employees

8

Headquarters

18575 Jamboree Road, Irvine, CA

Founded

2021

Frequently Asked Questions

;